HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Lewicki, Michelle ^a,b   Ng, Irene ^b,c   Schneider, Antoine G ^b,d  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN; CREATININE; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ACUTE KIDNEY FAILURE; ADVERSE EVENT; CARDIOPULMONARY BYPASS; CLINICAL OUTCOME; CREATININE BLOOD LEVEL; DRUG RESPONSE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HUMAN; META ANALYSIS; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ACUTE KIDNEY INJURY; ADULT; ADVERSE EFFECTS; BLOOD; CORONARY ARTERY BYPASS GRAFT; HEART SURGERY; LENGTH OF STAY;

ACUTE KIDNEY INJURY; ADULT; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; CREATININE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LENGTH OF STAY; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL REPLACEMENT THERAPY; SIMVASTATIN; SULFONAMIDES;

EID: 84942296134     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010480.pub2     Document Type: Review

References (136)

1. Almansob MA, Xu B, Zhou L, Hu XX, Chen W, Chang FJ, et al. Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: A randomized controlled trial. Arteriosclerosis Thrombosis & Vascular Biology 2012;32(9):2304-13. [MEDLINE: 22796581]
2. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agro F, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Critical Care Medicine 2006;34(3):660-7. [MEDLINE: 16505650]
3. Christenson JT. Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease. American Journal of Cardiology 2001;88(8):896-9. [MEDLINE: 11676957]
4. Christenson JT. Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. Cardiovascular Surgery 2001;9(1):33-43. [MEDLINE: 11137806]
5. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. European Journal of Cardio-Thoracic Surgery 1999;15(4):394-9. [MEDLINE: 10371111]
6. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. Journal of Thoracic & Cardiovascular Surgery 2008;136(6):1541-8. [MEDLINE: 19114204]
7. Prowle JR, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Haase M, et al. Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery. Nephrology 2012;17(3):215-24. [MEDLINE: 22117606]
8. Prowle JR, Licari E, Calzavacca P, Ligabo EV, Echeverri JE, Hasse M, et al. Peri-operative statin therapy does not alter the incidence of acute kidney injury after cardiopulmonary bypass: CREAT, the cardiopulmonary bypass, renal injury and atorvastatin trial. clinicaltrials.gov NCT00910221 [abstract]. Intensive Care Medicine 2010;36:S88. [EMBASE: 70290230]
9. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. Journal of Cardiovascular Pharmacology 2010;55(1):30-8. [MEDLINE: 19834333]
10. Tamayo E, Alonso O, Alvarez FJ, Castrodeza J, Florez S, di Stefano S. Effects of simvastatin on acute-phase protein levels after cardiac surgery [Efecto de la simvastatina en la concentracion de las proteinas de fase aguda despues de la cirugia cardiaca]. Medicina Clinica 2008;130(20):773-5. [MEDLINE: 18579030]
11. Tamayo E, Alvarez FJ, Alonso O, Bustamente R, Castrodeza J, Soria S, et al. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass. Journal of Cardiovascular Surgery 2009;50(5):687-94. [MEDLINE: 19741581]
12. Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagulation & Fibrinolysis 2010;21(8):750-7. [MEDLINE: 20962623]
13. Almeida R, Coelho OR, Meneses FH, Oliveira G, Molinari G, Franca R, et al. The APVS (atorvastatin in the perioperative of vascular surgery) study [abstract]. Circulation 2010;122(2):e345. [EMBASE: 70233157]
14. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010;122(11 Suppl):S66-73. [MEDLINE: 20837928]
15. Antoniades C, Bakogiannis C, Tousoulis D, Zhang MH, Demosthenous M, Antonopoulos A, et al. Preoperative atorvastatin treatment rapidly improves vein graft redox state by inhibiting rac1 and NADPH oxidase activity in patients undergoing elective CABG [abstract]. European Heart Journal 2010;31(Suppl 1):310. [EMBASE: 70280690]
16. Antoniades C, Demosthenous M, Margaritis M, Tousoulis D, Antonopoulos A, Paschalis A, et al. Short-term preoperative treatment with atorvastatin improves myocardial redox state in patients undergoing elective CABG by affecting NADPH oxidase activity and NOS coupling [abstract]. European Heart Journal 2010;31(Suppl 1):60. [EMBASE: 70279719]
17. Antoniades CA, Paschalis A, Tousoulis D, Bakogiannis C, Dimosthenous M, Antonopoulos AS, et al. Atorvastatin rapidly modifies vascular redox and increases nitric oxide bioavailability in human arteries [abstract]. Journal of the American College of Cardiology 2010;55(10 Suppl 1):A123. [EMBASE: 70096347]
18. Demosthenous M, Antoniades C, Paschalis A, Tousoulis D, Bakogiannis C, Antonopoulos AS, et al. Atorvastatin rapidly modifies vascular redox state and improves nitric oxide bioavailability in human vessels obtained from patients with advanced atherosclerosis [abstract]. European Heart Journal 2010;31(Suppl 1):1023. [EMBASE: 70283432]
19. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. American Journal of Cardiology 2011;108(1):1-7. [MEDLINE: 21529740]
20. Barbir M, Hunt BJ, Galloway D, Taylor A, Ilsley C, Mitchell A, et al. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clinical Cardiology 1994;17(2):59-64. [MEDLINE: 8162627]
21. Berkan O, Katrancioglu N, Ozker E, Ozerdem G, Bakici Z, Yilmaz MB. Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery. Thoracic & Cardiovascular Surgeon 2009;57(2):91-5. [MEDLINE: 19241310]
22. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. European Cytokine Network 2008;19(2):99-103. [MEDLINE: 18632424]
23. Chello M, Mastroroberto P, Patti G, D'Ambrosio A, Morichetti MC, Di Sciascio G, et al. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 2003;89(5):538-43. [MEDLINE: 12695460]
24. Chello M, Goffredo C, Patti G, Candura D, Melfi R, Mastrobuoni S, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. European Journal of Cardio-Thoracic Surgery 2005;28(6):805-10. [MEDLINE: 16274999]
25. Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo C, Di Sciascio G, et al. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Annals of Thoracic Surgery 2007;83(4):1374-80. [MEDLINE: 17383342]
26. Chen GL, Su JZ. Atorvastatin attenuated contrast induced renal function damage. Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2009;37(5):389-93. [MEDLINE: 19781210]
27. Cobbaert C, Sergeant P, Meyns B, Szecsi J, Kesteloot H. Time course of serum Lp(a) in men after coronary artery bypass grafting. Acta Cardiologica 1992;47(6):529-42. [MEDLINE: 1290314]
28. Coccia R, Spadaccio C, Foppoli C, Perluigi M, Covino E, Lusini M, et al. The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study. Clinical Therapeutics 2007;29(8):1706-17. [MEDLINE: 17919551]
29. Dotani MI, Morise AP, Haque R, Jain AC, Gupta N, Gibson CM. Association between short-term simvastatin therapy before coronary artery bypass grafting and postoperative myocardial blood flow as assessed by positron emission tomography. American Journal of Cardiology 2003;91(9):1107-9. [MEDLINE: 12714156]
30. Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van Poorten F, Bax JJ, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Annals of Surgery 2009;249(6):921-6. [MEDLINE: 19474688]
31. Caramelli B, Durazzo A, Ikeoka D, De Bernoche C, Monachini M, Puech Leao P, et al. Short-term treatment with atorvastatin for prevention of cardiac complications after vascular surgery [abstract no: 086]. Atherosclerosis Supplements 2002;3(2):83. [CENTRAL: CN-00831428]
32. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. Journal of Vascular Surgery 2004;39(5):967-75. [MEDLINE: 15111846]
33. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy 2000;20(4):410-6. [MEDLINE: 10772372]
34. Flaker GC, Warnica JW, Sacks FM, Moye LA, Davis BR, Rouleau JL, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. Journal of the American College of Cardiology 1999;34(1):106-12. [MEDLINE: 10399998]
35. Lloyd GW, Jackson G, Foley DP, Boersma E, Shepherd J, Serruys PW. The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis 2001;158(2):445-54. [MEDLINE: 11583725]
36. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. European Heart Journal 1999;20(1):58-69. [MEDLINE: 10075142]
37. Florens E, Salvi S, Peynet J, Elbim C, Mallat Z, Bel A, et al. Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study. Journal of Cardiac Surgery 2001;16(3):232-9. [MEDLINE: 11824669]
38. Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, et al. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group. American Journal of Cardiology 1994;73(14):50D-61D. [MEDLINE: 8198025]
39. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. Journal of the American College of Cardiology 2014;63(1):62-70. [MEDLINE: 24076297]
40. Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circulation Journal 2009;73(12):2244-9. [MEDLINE: 19822977]
41. Kesteloot H, Cobbaert C, Meyns B, Szecsi J, Lesaffre E, Sergeant P. Time course of serum lipid and lipoprotein levels after coronary bypass surgery: modification by pravastatin. Acta Cardiologica 1992;47(6):519-28. [MEDLINE: 1290313]
42. Kourliouros A, Valencia O, Hosseini MT, Mayr M, Sarsam M, Camm J, et al. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. Journal of Thoracic & Cardiovascular Surgery 2011;141(1):244-8. [MEDLINE: 20624624]
43. Krivoy N, Adler Z, Saloma R, Hawadie A, Azzam ZS. Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Experimental & Clinical Cardiology 2008;13(4):171-4. [EMBASE: 2009154149]
44. Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology 2012;122(3):195-202. [MEDLINE: 22854323]
45. Arampatzis CA, Goedhart D, Serruys PW, Saia F, Lemos PA, de Feyter P, et al. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal 2005;149(2):329-35. [MEDLINE: 15846273]
46. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3215-22. [MEDLINE: 12076217]
47. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP, TIMI 22 Investigators. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. American Heart Journal 2008;155(5):954-8. [MEDLINE: 18440347]
48. Ludman AJ, Hausenloy DJ, Venugopal V, Babu G, Boston-Griffiths E, Lawrence D, et al. The effect of high-dose atorvastatin on a background of standard-dose chronic statin therapy in patients undergoing cardiac surgery [abstract]. European Heart Journal 2010;31(Suppl 1):70. [EMBASE: 70279760]
49. Morawietz H, Erbs S, Holtz J, Schubert A, Krekler M, Goettsch W, et al. Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial. Circulation 2006;114(1 Suppl):1296-301. [MEDLINE: 16820589]
50. Nakamura K, Masuda H, Kariyazono H, Arima J, Iguro Y, Yamada K, et al. Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting. Cytokine 2006;36(5-6):201-10. [MEDLINE: 17300951]
51. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61(7):711-4. [MEDLINE: 20395226]
52. Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, et al. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis 1999;146(2):369-79. [MEDLINE: 10532693]
53. Campeau L, Lesperance J, Bilodeau L, Fortier A, Guertin MC, Knatterud GL. Effect of cholesterol lowering and cardiovascular risk factors on the progression of aortoiliac arteriosclerosis: a quantitative cineangiography study. Angiology 2005;56(2):191-9. [MEDLINE: 15793608]
54. Canner PL, Thompson B, Knatterud GL, Geller N, Campeau L, Zucker D. An application of the Zucker-Wittes modified ratio estimate statistic in the Post Coronary Artery Bypass Graft (CABG) clinical trial. Controlled Clinical trials 1997;18(4):318-27. [MEDLINE: 9257071]
55. Domanski M, Tian X, Fleg J, Coady S, Gosen C, Kirby R, et al. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial. American Journal of Cardiology 2008;102(8):1023-7. [MEDLINE: 18929703]
56. Hunninghake DB. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. American Journal of Medicine 1998;104(2A):9S-13S. [MEDLINE: 9550501]
57. Mukamal KJ, Girotra S, Mittleman MA. Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts. American Heart Journal 2006;151(2):368-72. [MEDLINE: 16442902]
58. Mukamal KJ, Smith CC, Karlamangla AS, Moore AA. Moderate alcohol consumption and safety of lovastatin and warfarin among men: the post-coronary artery bypass graft trial. American Journal of Medicine 2006;119(5):434-40. [MEDLINE: 16651056]
59. Mukamal KJ, Wellenius GA, Mittleman MA. Hematologic parameters, atherosclerotic progression, and prognosis in patients with previous coronary artery bypass grafting (from the Post CABG Trial). American Journal of Cardiology 2009;103(3):328-32. [MEDLINE: 19166684]
60. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts [erratum appears in N Engl J Med 1997 Dec 18;337(25):1859]. New England Journal of Medicine 1997;336(3):153-62. [MEDLINE: 8992351]
61. Wee CC, Girotra S, Weinstein AR, Mittleman MA, Mukamal KJ. The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy. Journal of the American College of Cardiology 2008;52(8):620-5. [MEDLINE: 18702964]
62. Wellenius GA, Mukamal KJ, Winkelmayer WC, Mittleman MA. Renal dysfunction increases the risk of saphenous vein graft occlusion: results from the Post-CABG trial. Atherosclerosis 2007;193(2):414-20. [MEDLINE: 16905139]
63. White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, et al. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 2001;104(22):2660-5. [MEDLINE: 11723015]
64. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). Journal of the American College of Cardiology 2014;63(1):71-9. [MEDLINE: 24076283]
65. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. American Heart Journal 2008;155(3):499. [MEDLINE: 18294484]
66. Qian YJ, Xiao XJ, Yuan HS, Tang H, Shao HZ, Wei DM. Combination pharmacological cardioversion of permanent atrial fibrillation in post-prosthetic mitral valve replacement outpatients: a novel approach for the treatment of atrial fibrillation. Journal of International Medical Research 2008;36(3):537-43. [MEDLINE: 18534136]
67. Radaelli A, Loardi C, Cazzaniga M, Balestri G, DeCarlini C, Cerrito MG, et al. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arteriosclerosis, Thrombosis & Vascular Biology 2007;27(12):2750-5. [MEDLINE: 17823365]
68. Billings FT, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. Journal of Cardiothoracic & Vascular Anesthesia 2010;24(6):913-20. [MEDLINE: 20599398]
69. Riahi S, Schmidt EB, Amanavicius N, Karmisholt J, Jensen HS, Christoffersen RP, et al. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. International Journal of Cardiology 2006;111(3):436-41. [MEDLINE: 16290290]
70. Sasmazel A, Baysal A, Fedekar A, Buyukbayrak F, Bugra O, Erdem H, et al. The effect of statin therapy on stimulation of endothelium-derived nitric oxide before and after coronary artery bypass surgery. Heart Surgery Forum 2010;13(4):E243-6. [MEDLINE: 20719727]
71. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. Journal of Vascular Surgery 2008;47(4):774-81. [MEDLINE: 18381138]
72. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. New England Journal of Medicine 2009;361(10):980-9. [MEDLINE: 19726772]
73. Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. American Heart Journal 2008;156(2):373-16. [MEDLINE: 18657672]
74. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. [Erratum appears in JACC Cardiovasc Interv. 2012 Feb;5(2):248]. JACC: Cardiovascular Interventions 2010;3(3):332-9. [MEDLINE: 20298994]
75. Su JZ, Xue Y, Cai WQ, Huang QY, Chai DJ, Chen GL, et al. Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin. Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2011;39(9):807-11. [MEDLINE: 22321227]
76. Sun YF, Mei YQ, Ji Q, Wang XS, Feng J, Cai JZ, et al. Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2009;89(42):2988-91. [MEDLINE: 20137710]
77. Tetik S, Ak K, Isbir S, Eksioglu-Demiralp E, Arsan S, Iqbal O, et al. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clinical & Applied Thrombosis/Hemostasis 2010;16(2):189-98. [MEDLINE: 19703819]
78. Toso A, Leoncini M, Maioli M, Gallopin M, Tedeschi D, Amato M, et al. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. Journal of Cardiovascular Medicine 2011;12(5):318-21. [MEDLINE: 21045713]
79. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. American Journal of Cardiology 2010;105(3):288-92. [MEDLINE: 20102936]
80. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. American Journal of Cardiology 2009;104(4):519-24. [MEDLINE: 19660605]
81. Zhou X, Jin YZ, Wang Q, Min R, Zhang XY. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2009;37(5):394-6. [MEDLINE: 19781211]
82. Zhou Q, Wang G, Gao C, Chen T. Effect of ulinastatin on perioperative inflammatory response to coronary artery bypass grafting with cardiopulmonary bypass. Zhong Nan da Xue Xue Bao. Yi Xue Ban [Journal of Central South University Medical Sciences] 2010;35(2):107-10. [MEDLINE: 20197607]
83. de Oliveira MS, Martins KB, Costa JR Jr, Abizaid A, Stadler J, Mattos LA, et al. Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users [Impacto na funcao renal de uma dose de reforco de rosuvastatina previa a intervencao coronaria percutanea eletiva nos pacientes em uso cronico de estatina]. Revista Brasileira de Cardiologia Invasiva 2012;20(3):303-8. [EMBASE: 2013021434]
84. Han S, Li XM, Mohammed Ali LA, Fu NK, Jin DX, Cong HL. Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures. International Journal of Cardiology 2013;168(5):5101-3. [MEDLINE: 23972962]
85. Liu WJ, Zhang BC, Guo R, Wei YD, Li WM, Xu YW. Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography. Chinese Medical Journal 2013;126(18):3475-80. [MEDLINE: 24034093]
86. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. Journal of the American College of Cardiology 2009;54(23):2157-63. [MEDLINE: 19664895]
87. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012;126(25):3008-16. [MEDLINE: 23147173]
88. Kaya A, Kurt M, Tanboga IH, Isik T, Ekinci M, Aksakal E, et al. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Acta Cardiologica 2013;68(5):489-94. [MEDLINE: 24283110]
89. Zhou S. Anti-inflammatory and renoprotective effect of pretreatment loading dose atorvastatin in CABG. www.clinicaltrials.gov/ct2/show/NCT01547455 (accessed 13 January 2015).
90. Billings FT , Ball SK, Roberts LJ, Pretorius M. Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response. Free Radical Biology & Medicine 2011;50(11):1480-7. [MEDLINE: 21334433]
91. Ali IS, Buth KJ. Preoperative statin use and in-hospital outcomes following heart surgery in patients with unstable angina. European Journal of Cardio-Thoracic Surgery 2005;27(6):1051-6. [MEDLINE: 15896616]
92. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(5):1266-73. [MEDLINE: 18667735]
93. Asimakopoulos G, Karagounis AP, Valencia O, Alexander N, Howlader M, Sarsam MA, et al. Renal function after cardiac surgery off- versus on-pump coronary artery bypass: analysis using the Cockroft-Gault formula for estimating creatinine clearance. Annals of Thoracic Surgery 2005;79(6):2024-31. [MEDLINE: 15919303]
94. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. [Erratum appears in Lancet. 2008 Jun 21;371(9630):2084], [Erratum appears in Lancet. 2005 Oct 15-21;366(9494):1358]. Lancet 2005;366(9493):1267-78. [MEDLINE: 16214597]
95. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 2004;8(4):R204-12. [MEDLINE: 15312219]
96. Billings FT, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. Journal of Cardiothoracic & Vascular Anesthesia 2010;24(6):913-20. [MEDLINE: 20599398]
97. Bove T, Calabrò MG, Landoni G, Aletti G, Marino G, Crescenzi G, et al. The incidence and risk of acute renal failure after cardiac surgery. Journal of Cardiothoracic & Vascular Anesthesia 2004;18(4):442-5. [MEDLINE: 15365924]
98. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Annals of Thoracic Surgery 1997;63(1):277-84. [MEDLINE: 8993292]
99. Chawla LS, Zhao Y, Lough FC, Schroeder E, Seneff MG, Brennan JM. Off-pump versus on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function. Journal of the American Society of Nephrology 2012;23(8):1389-97. [MEDLINE: 22595302]
100. Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F, et al. Preoperative renal risk stratification. Circulation 1997;95(4):878-84. [MEDLINE: 9054745]
101. Chukwuemeka A, Weisel A, Maganti M, Nette AF, Wijeysundera DN, Beattie WS, et al. Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis. Annals of Thoracic Surgery 2005;80(6):2148-53. [MEDLINE: 16305860]
102. Clark LL, Ikonomidis JS, Crawford FA Jr, Crumbley A, Kratz JM, Stroud MR, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. Journal of Thoracic & Cardiovascular Surgery 2006;131(3):679-85. [MEDLINE: 16515923]
103. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. American Journal of Kidney Diseases 2009;53(6):961-73. [MEDLINE: 19346042]
104. Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP, et al. Acute renal failure following cardiac surgery. Nephrology Dialysis Transplantation 1999;14(5):1158-62. [MEDLINE: 10344355]
105. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833]
106. Devarajan P. Update on mechanisms of ischemic acute kidney injury. Journal of the American Society of Nephrology 2006;17(6):1503-20. [MEDLINE: 16707563]
107. Egger M, Davey Smith G, Phillips AN. Meta-analysis: Principles and procedures. BMJ 1997;315(7121):1533-7. [MEDLINE: 9432252]
108. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Letters 1976;72(2):323-6. [MEDLINE: 16386050]
109. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. Journal of the American Society of Nephrology 2002;13(9):2288-98. [MEDLINE: 12191973]
110. Haslinger-Löffler B. Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function. Kidney International 2008;74(5):553-5. [MEDLINE: 18709024]
111. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
112. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
113. Inman SR, Davis NA, Mazzone ME, Olson KM, Lukaszek VA, Yoder KN. Simvastatin and L-arginine preserve renal function after ischemia/reperfusion injury. American Journal of the Medical Sciences 2005;329(1):13-7. [MEDLINE: 15654174]
114. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. American Heart Journal 2008;155(3):499, e1-8. [MEDLINE: 18294484]
115. Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009;119(4):495-502. [MEDLINE: 19153273]
116. Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. Journal of the American Society of Nephrology 2010;21(2):345-52. [MEDLINE: 20019168]
117. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. New England Journal of Medicine 2012;366(16):1489-97. [MEDLINE: 22449296]
118. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 2012;7(4):e34450. [MEDLINE: 22511942]
119. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dörge H, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30, 000 patients. European Heart Journal 2008;29(12):1548-59. [MEDLINE: 18506053]
120. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: ]
121. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Annals of Internal Medicine 1998;128(3):194-203. [MEDLINE: 9454527]
122. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute kidney injury: a relevant complication after cardiac surgery. Annals of Thoracic Surgery 2011;92(4):1539-47. [MEDLINE: 21872837]
123. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care 2007;11(2):R31. [MEDLINE: 17331245]
124. Mistiaen W, Van Cauwelaert P, Muylaert P, De Worm E. A thousand pericardial valves in aortic position: risk factors for postoperative acute renal function impairment in elderly. Journal of Cardiovascular Surgery 2009;50(2):233-7. [MEDLINE: 18948862]
125. Morgan C, Zappitelli M, Gill P. Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review. Critical Care 2009;13(5):R165. [MEDLINE: 19840397]
126. Ostermann ME, Taube D, Morgan CJ, Evans TW. Acute renal failure following cardiopulmonary bypass: a changing picture. Intensive Care Medicine 2000;26(5):565-71. [MEDLINE: 10923731]
127. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61(7):711-4. [MEDLINE: 20395226]
128. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004;110(11 Suppl 1):II45-9. [MEDLINE: 15364837]
129. Patti G. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. Journal of Cardiovascular Medicine 2011;12(5):305-8. [MEDLINE: 21451331]
130. Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA, BEST Kidney Investigators. Cost of acute renal replacement therapy in the intensive care unit: results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) study. Critical Care 2010;14(2):R46. [MEDLINE: 20346163]
131. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;327(7304):101-5. [MEDLINE: 11451790]
132. Swaminathan M, Shaw AD, Phillips-Bute BG, McGugan-Clark PL, Archer LE, Talbert S, et al. Trends in acute renal failure associated with coronary artery bypass graft surgery in the United States. Critical Care Medicine 2007;35(10):2286-91. [MEDLINE: 17944016]
133. Tabata M, Khalpey Z, Pirundini PA, Byrne ML, Cohn LH, Rawn JD. Renoprotective effect of preoperative statins in coronary artery bypass grafting. American Journal of Cardiology 2007;100(3):442-4. [MEDLINE: 17659925]
134. Thakar CV, Liangos O, Yared JP, Nelson D, Piedmonte MR, Hariachar S, et al. ARF after open-heart surgery: Influence of gender and race. American Journal of Kidney Diseases 2003;41(4):742-51. [MEDLINE: 12666060]
135. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, et al. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. American Journal of Nephrology 2003;23(1):13-7. [MEDLINE: 12373076]
136. Lewicki M, Ng I, Schneider AG. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: ]